Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Intrathecal Administration of Nivolumab for Leptomeningeal Disease in Metastatic Solid Tumors: Dose Escalation Findings from the Multicenter IT-PD1/NOA-26 Phase 1 Study

  • By

  • Ghazaleh Tabatabai

  • Isabel Ramirez

  • Beatrix Welte

  • Paula Bombach

  • Hannes Becker

  • Denise Bernhardt

  • Regine Mayer-Steinacker

  • Friedegund Meier

  • Nicolas Neidert

  • Roland Roelz

  • Iris Mildenberger

  • Lukas Bunse

  • Michael Platten

  • Ulrich Herrlinger

  • Uwe M. Martens

  • Ulrike Ernemann

  • Manuela Neumann

  • Marcos Tatagiba

  • Lina Maria Serna-Higuita

  • Peter Martus

  • Mirjam Renovanz

  • June 4, 2026

Share

Clinical Scorecard: Intrathecal Administration of Nivolumab for Leptomeningeal Disease in Metastatic Solid Tumors: Dose Escalation Findings from the Multicenter IT-PD1/NOA-26 Phase 1 Study

At a Glance

CategoryDetail
Condition
Key MechanismsIntrathecal administration of nivolumab as an immune checkpoint inhibitor (source needed).
Target Population
Care Setting

Key Highlights

  • Remove unsupported phrases.

Guideline-Based Recommendations

Diagnosis

    Management

    • A
    • t
    • t
    • r
    • i
    • b
    • u
    • t
    • i
    • o
    • n
    • n
    • e
    • e
    • d
    • e
    • d
    • f
    • o
    • r
    • '
    • m
    • a
    • i
    • n
    • s
    • t
    • a
    • y
    • t
    • h
    • e
    • r
    • a
    • p
    • i
    • e
    • s
    • '
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adults with confirmed diagnosis of LMD and good-risk profile.

        Intrathecal nivolumab administered every 2 weeks for a total of six applications.

        Clinical Best Practices

        • remove

        Related Resources & Content

        Original Source(s)

        Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

        • by Ghazaleh Tabatabai, Isabel Ramirez, Beatrix Welte, Paula Bombach, Hannes Becker, Denise Bernhardt, Regine Mayer-Steinacker, Friedegund Meier, Nicolas Neidert, Roland Roelz, Iris Mildenberger, Lukas Bunse, Michael Platten, Ulrich Herrlinger, Uwe M. Martens, Ulrike Ernemann, Manuela Neumann, Marcos Tatagiba, Lina Maria Serna-Higuita, Peter Martus, Mirjam Renovanz

        • June 4, 2026

        Related Content

        Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

        Predictors of Delayed and Omitted Postoperative Radiotherapy After Laryngectomy for pT4 Laryngeal Cancer

        Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

        All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

        • September 16, 2026

        • 2 min